PerkinElmer's Oxford Immunotec receives U.S. FDA approval for T-cell select to automate clinically superior tuberculosis detection
PerkinElmer’s (NYSE: PKI) Oxford Immunotec today announced the U.S. Food and Drug Administration (FDA) has approved the use of the T-Cell Select™ reagent kit for the automation of its T-SPOT®.TB test workflow for in vitro diagnostic (IVD) use by certified laboratories.
Source: news-medical.net